Comparative Pharmacology
Head-to-head clinical analysis: DRICORT versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRICORT versus ORTIKOS.
DRICORT vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with predominant glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell function.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
DRICORT (dexamethasone) typical adult dose: 0.5-9 mg/day orally in divided doses every 6-12 hours, or 0.5-24 mg IV/IM once or divided. Anti-inflammatory: 0.75-9 mg/day PO/IV in 2-4 divided doses. Severe conditions: up to 16 mg/day in divided doses. Short-term high-dose: up to 40-100 mg IV push for specific indications.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Terminal elimination half-life is 10-12 hours in adults with normal renal function, allowing twice-daily dosing.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal (80-85% as unchanged drug and metabolites), with 15-20% excreted in feces via biliary elimination.
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category C
Category C
Corticosteroid
Corticosteroid